Mucosal immunization with DNA vaccines

Microbes and Infection

Volumn 1, Issue 9, 1999, Pages 685-698

  McCluskie, Michael J ^a,b   Davis, Heather L ^a,b,c,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b U ^*  (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d PFIZER INC   (United States)

Author keywords

DNA vaccines; Genetic vaccination; Mucosal immunization

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN; CYTOKINE; DNA VACCINE; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; MEASLES VACCINE; MICROSPHERE; PLASMID DNA; POLYGLACTIN; QS 21; SAPONIN; VIRUS VACCINE;

BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSTIMULATION; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); HERPES; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032745265     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80070-7     Document Type: Review

References (144)

1. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
2. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
3. Davis H.L., Brazolot Millan C.L., Watkins S.C. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Therapy. 4:1997;181-188.
4. Casares S., Inaba K., Brumeanu T.D., Steinman R.M., Bona C.A. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. M. 186:1997;1481-1486.
5. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D., Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. M. 2:1996;1122-1128.
6. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
7. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
8. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
9. Davis H.L., McCluskie M.J. DNA vaccines for viral diseases. Microbes Infect. 1:1999;7-23.
10. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system from fundamental concepts to vaccine development. Vaccine. 10:1992;75-88.
11. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 13:1995;1589-1595.
12. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J.P., Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:1994;15-23.
13. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 90:1993;11478-11482.
14. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immunol. 6:1994;572-583.
15. Lamm M.E. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51:1997;311-340.
16. Tomasi T.B. Overview of the mucosal system. Ogra P.L, et al. Handbook of Mucosal Immunity. 1994;1-8 Academic Press, Inc., San Diego.
17. Sabbaj S., Kiyono H., McGhee J.R. Mucosal immunization for enteric diseases current practise and future prospects. BioDrugs. 7:1997;134-157.
18. Brandtzaeg P., Jahnsen F.L., Farstad I.N. Immune functions and immunopathology of the mucosa of the upper respiratory pathways. Acta Otolaryngol. (Stockh). 116:1996;149-159.
19. Brandtzaeg P., Farstad I.N., Haraldsen G., Jahnsen F.L. Cellular and molecular mechanisms for induction of mucosal immunity. Dev. Biol. Stand. 92:1998;93-108.
20. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:1992;2277-2281.
21. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:1992;622-647.
22. Rappuoli R., Douce G., Dougan G., Pizza M. Genetic detoxification of bacterial toxins a new approach to vaccine development. Int. Arch. Allergy App. Immunol. 108:1995;327-333.
23. Giuliani M.M., DelGiudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP- ribosyltransferase activity. J. Exp. M. 187:1998;1123-1132.
24. Mestecky J., Michalek S.M., Moldoveanu Z., Russell M.W. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring. Inst. Mitt. 98:1997;33-43.
25. Naficy A., Rao M.R., Paquet C., Antona D., Sorkin A., Clemens J.D. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings a cost-effectiveness analysis. JAMA. 279:1998;521-525.
26. Douglas R.G.J.R. The Children's Vaccine Initiative - will it work? J. Infect. Dis. 168:1993;269-274.
27. Davis H.L., Michel M.L., Whalen R.G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2:1993;1847-1851.
28. McCluskie M.J., Davis H.L. DNA-based immunization of mice against hepatitis B by intramuscular injection requires free DNA. Brown F, et al. Vaccines 97: Molecular approaches to the control of infectious diseases. 1997;125-130 Cold Spring Harbor Laboratory Press New York.
29. Gregoriadis G., Saffie R., DeSouza J.B. Liposome-mediated DNA vaccination. FEBS Lett. 402:1997;107-110.
30. Wolff J.A., Ludtke J.J., Acsadi G., Williams P., Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1:1992;363-369.
31. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., Gromkowski S.H., Singh M., Lew D., Yankauckas M.A., Baird S.M., Rhodes G.H. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. USA. 91:1994;9519-9523.
32. Kuklin N., Daheshia M., Karem K., Manickan E., Rouse B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:1997;3138-3145.
33. Sasaki S., Hamajima K., Fukushima J., Ihata A., Ishii N., Gorai I., Hirahara F., Mohri H., Okuda K. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect. Immun. 66:1998;823-826.
34. Sasaki S., Sumino K., Hamajima K., Fukushima J., Ishii N., Kawamoto S., Mohri H., Kensil C.R., Okuda K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72:1998;4931-4939.
35. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., Fukushima J., Miyazaki J., Wahren B., Okuda K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:1997;3638-3647.
36. Klavinskis L.S., Barnfield C., Gao L., Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J. Immunol. 162:1999;254-262.
37. Hinkula J., Lundholm P., Wahren B. Nucleic acid vaccination with HIV regulatory genes a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine. 15:1997;874-878.
38. Etchart N.R., Buckland R., Liu M.A., Wild T.F., Kaiserlian D. Class I-restricted induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J. Gen. Virol. 78:1997;1577-1580.
39. Ishii N., Fukushima J., Kaneko T., Okada E., Tani K., Tanaka S.I., Hamajima K., Xin K.Q., Kawamoto S., Koff W., Nishioka K., Yasuda T., Okuda K. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 13:1997;1421-1428.
40. Asakura Y., Hinkula J., Leandersson A.C., Fukushima J., Okuda K., Wahren B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand. J. Immunol. 46:1997;326-330.
41. Hamajima K., Sasaki S., Fukushima J., Kaneko T., Xin K.Q., Kudoh I., Okuda K. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. 88:1998;205-210.
42. Bagarazzi M.L., Boyer J.D., Javadian M.A., Chattergoon M., Dang K., Kim G., Shah J., Wang B., Weiner D.B. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. J. Med. Primatol. 26:1997;27-33.
43. Wang B., Dang K., Agadjanyan M.G., Srikantan V., Li F., Ugen K.E., Boyer J., Merva M., Williams W.V., Weiner D.B. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine. 15:1997;821-825.
44. Daheshia M., Kuklin N., Manickan E., Chun S., Rouse B.T. Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine. 16:1998;1103-1110.
45. Haynes J.R., McCabe D.E., Swain W.F., Widera G., Fuller J.T. Particle-mediated nucleic acid immunization. J. Biotechnol. 44:1996;37-42.
46. Keller E.T., Burkholder J.K., Shi F., Pugh T.D., McCabe D., Malter J.S., Macewen E.G., Yang N.S., Ershler W.B. In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. Cancer Gene Ther. 3:1996;186-191.
47. Livingston J.B., Lu S., Robinson H., Anderson D.J. Immunization of the female genital tract with a DNA-based vaccine. Infect. Immun. 66:1998;322-329.
48. Winchell J.M., Routray S., Betts P.W., Van Kruiningen H.J., Silbart L.K. Mucosal and systemic antibody responses to a C4/V3 construct following DNA vaccination of rabbits via the Peyer's patch. J. Infect. Dis. 178:1998;850-853.
49. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., Hinshaw V.S., Swain W.F. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J. Virol. 72:1998;1491-1496.
50. Tanelian D.L., Barry M.A., Johnston S.A., Le T., Smith G. Controlled gene gun delivery and expression of DNA within the cornea. Biotechniques. 23:1997;484-488.
51. Lasic D.D., Templeton N.S. Liposomes in gene therapy. Adv. Drug Del. Rev. 20:1996;221-266.
52. Miller A.D. Human gene therapy comes of age. Nature. 357:1992;455-460.
53. Ledley F.D. Nonviral gene therapy the promise of genes as pharmaceutical products. Hum. Gene Ther. 6:1995;1129-1144.
54. Masuda I., Matsuo T., Yasuda T., Matsuo N. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest. Ophthalmol. Vis. Sci. 37:1996;1914-1920.
55. Mitchell W.M., Rosenbloom S.T., Gabriel J. Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes. Immunotechnology. 1:1995;211-219.
56. Klavinskis L.S., Gao L., Barnfield C., Lehner T., Parker S. Mucosal immunization with DNA-liposome complexes. Vaccine. 15:1997;818-820.
57. Xin K.Q., Hamajima K., Sasaki S., Honsho A., Tsuji T., Ishii N., Cao X.R., Lu Y., Fukushima J., Shapshak P., Kawamoto S., Okuda K. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology. 94:1998;438-444.
58. Ban E.M., Van Ginkel F.W., Simecka J.W., Kiyono H., Robinson H.L., McGhee J.R. Mucosal immunization with DNA encoding influenza hemagglutinin. Vaccine. 15:1997;811-813.
59. Pal S., Barnhart K.M., Wei Q., Abai A.M., Peterson E.M., De LaMaza L.M. Vaccination of mice with DNA plasmids coding for Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine. 17:1999;459-465.
60. Felgner P.L., Tsai Y.J., Sukhu L., Wheeler C.J., Manthorpe M., Marshall J., Cheng S.H. Improved cationic lipid formulations for in vivo gene therapy. Ann. NY Acad. Sci. 772:1996;126-139.
61. Meyer K.B., Thompson M., Levy M., Barron L., Szoka F.J. Intratracheal gene delivery to the mouse airway characterization of plasmid DNA expression and pharmacokinetics. Gene Ther. 2:1995;450-460.
62. McCluskie M.J., Chu Y., Xia J.L., Jessee J., Gebyehu G., Davis H.L. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. 8:1998;401-414.
63. Hazinski T.A., Ladd P.A., Dematteo C.A. Localization and induced expression of fusion genes in the rat lung. Am. J. Respir. Cell Mol. Biol. 4:1991;206-209.
64. Wheeler C.J., Felgner P., Tsai Y.J., Marshall J., Sukhu L., Doh S.G., Hartikka J., Nietupski J., Manthorpe M., Nichols M., Plewe M., Liang X., Norman J., Smith A., Cheng S.H. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc. Natl. Acad. Sci. USA. 93:1996;11454-11459.
65. Scheule R.K., St George J.A., Bagley R.G., Marshall J., Kaplan J.M., Akita G.Y., Wang K.X., Lee E.R., Harris D.J., Jiang C., Yew N.S., Smith A.E., Cheng S.H. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8:1997;689-707.
66. Lee E.R., Marshall J., Siegel C.S., Jiang C.W., Yew N.S., Nichols M.R., Nietupski J.B., Ziegler R.J., Lane M.B., Wang K.X., Wan N.C., Scheule R.K., Harris D.J., Smith A.E., Cheng S.H. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum. Gene Ther. 7:1996;1701-1717.
67. Xiang Z.Q., He Z., Wang Y., Ertl H.C.J. The effect of interferon-γ on genetic immunization. Vaccine. 15:1997;896-898.
68. Harms J.S., Splitter G.A. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6:1995;1291-1297.
69. Romero R., Lavine J.E. Cytokine inhibition of the hepatitis B virus core promoter. Hepatology. 23:1996;17-23.
70. Yew N.S., Wysokenski D.M., Wang K.X., Ziegler R.J., Marshall J., McNeilly D., Cherry M., Osburn W., Cheng S.H. Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum. Gene Ther. 8:1997;575-584.
71. Freimark B.D., Blezinger H.P., Florack V.J., Nordstrom J.L., Long S.D., Deshpande D.S., Nochumson S., Petrak K.L. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid cationic lipid complexes. J. Immunol. 160:1998;4580-4586.
72. Schwartz D.A., Quinn T.J., Thorne P.S., Sayeed S., Yi A.K., Krieg A.M. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest. 100:1997;68-73.
73. Krieg A.M., Wu T., Weeratna R., Efler S., Love-Homan L., Yang L., Yi A.E., Short D., Davis H.L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA. 95:1998;12631-12636.
74. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunology. 81:1994;661-667.
75. O'Hagan D.T., Rahman D., Jeffery H., Sharif S., Challacombe S.J. Controlled release microparticles for oral immunization. Int. J. Pharmacol. 108:1994;133-139.
76. Gupta R.K., Chang A.C., Siber G.R. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev. Biol. Stand. 92:1998;63-78.
77. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable microsphere as potential oral delivery systems. Nature. 386:1997;410-414.
78. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 15:1997;814-817.
79. Jones D.H., Clegg J.C., Farrar G.H. Oral delivery of micro-encapsulated DNA vaccines. Dev. Biol. Stand. 92:1998;149-155.
80. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg H.B., Herrmann J.E. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 72:1998;5757-5761.
81. Ramani K., Bora R.S., Kumar M., Tyagi S.K., Sarkar D.P. Novel gene delivery to liver cells using engineered virosomes. FEBS Lett. 404:1997;164-168.
82. Ramani K., Hassan Q., Venkaiah B., Hasnain S.E., Sarkar D.P. Site-specific gene delivery in vivo through engineered Sendai viral envelopes. Proc. Natl. Acad. Sci. USA. 95:1998;11886-11890.
83. Qin L., Pahud D.R., Ding Y., Bielinska A.U., Kukowska-Latallo J.F., Baker J.R., Jr, Bromberg J.S. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine dendrimers. Hum. Gene Ther. 9:1998;553-560.
84. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R.J.R. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA. 93:1996;4897-4902.
85. Leong K.W., Mao H.Q., Truong-Le V.L., Roy K., Walsh S.M., August J.T. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Controlled Release. 53:1998;183-193.
86. Phillips S.C. Receptor-mediated DNA delivery approaches to human gene therapy. Biologicals. 23:1995;13-16.
87. Vogel F.R. Adjuvants in perspective. Dev. Biol. Stand. 92:1998;241-248.
88. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11:1993;1179-1184.
89. Verweij W.R., De Haan L., Holtrop M., Agsteribbe E., Brands R., Van Scharrenburg G.J., Wilschut J. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine. 16:1998;2069-2076.
90. Fontana M.R., Manetti R., Giannelli V., Magagnoli C., Marchini A., Olivieri R., Domenighini M., Rappuoli R., Pizza M. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:1995;2356-2360.
91. Chong C., Friberg M., Clements J.D. LT (R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine. 1998;16732-16740.
92. Douce G., Giuliani M.M., Giannelli V., Pizza M.G., Rappuoli R., Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine. 1998;161065-161073.
93. Komase K., Tamura S., Matsuo K., Watanabe K., Hattori N., Odaka A., Suzuki Y., Kurata T., Aizawa C. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine. Vaccine. 16:1998;248-254.
94. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F.W., Noda M., Takeda Y., McGhee J.R. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA. 94:1997;5267-5272.
95. Yamamoto S., Takeda Y., Yamamoto M., Kurazono H., Imaoka K., Yamamoto M., Fujihashi K., Noda M., Kiyono H., McGhee J.R. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. M. 185:1997;1203-1210.
96. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., Okahashi N., Yamamoto M., Kiyono H., Bluethmann H., Fujihashi K., McGhee J.R. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:1995;4621-4629.
97. Imaoka K., Miller C.J., Kubota M., McChesney M.B., Lohman B., Yamamoto M., Fujihashi K., Someya K., Honda M., McGhee J.R., Kiyono H. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161:1998;5952-5958.
98. Hornquist E., Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:1993;2136-2143.
99. Wiedermann U., Jahn-Schmid B., Fritsch R., Bauer L., Renz H., Kraft D., Ebner C. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. Clin. Exp. Immunol. 111:1998;144-151.
100. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., Van Hoogevest P., VanNest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:1995;277-296.
101. Sasaki S., Tsuji T., Hamajima K., Fukushima J., Ishii N., Kaneko T., Xin K.Q., Mohri H., Aoki I., Okubo T., Nishioka K., Okuda K. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immun. 65:1997;3520-3528.
102. Wang D., Robinson D.R., Kwon G.S., Samuel J. Encapsulation of plasmid DNA in biodegradable poly (D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Controlled Release. 57:1999;9-18.
103. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431-437.
104. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., Chisari F.V. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. USA. 91:1994;3764-3768.
105. Lebman D.A., Coffman R.L. Cytokines in the mucosal immune system. Ogra P.L, et al. Handbook of Mucosal Immunity. 1994;243-250 Academic Press, Inc., San Diego.
106. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., McGhee J.R. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. M. 185:1997;415-427.
107. Marinaro M., Boyaka P.N., Jackson R.J., Finkelman F.D., Kiyono H., Jirillo E., McGhee J.R. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:1999;114-121.
108. Arulanandam B.P., Metzger D.W. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 3:1999;252-260.
109. Hamajima K., Fukushima J., Bukawa H., Kaneko T., Tsuji T., Asakura Y., Sasaki S., Xin K.Q., Okuda K. Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. Clin. Immunol. Immunopathol. 83:1997;179-184.
110. Li X.M., Chopra R.K., Chou T.Y., Schofield B.H., Wills-Karp M., Huang S.K. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J. Immunol. 157:1996;3216-3219.
111. Hogan S.P., Foster P.S., Tan X., Ramsay A.J. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur. J. Immunol. 28:1998;413-423.
112. Daheshia M., Kuklin N., Kanangat S., Manickan E., Rouse B.T. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J. Immunol. 159:1997;1945-1952.
113. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Immunomodulation by mucosal gene transfer using TGF-beta DNA. J. Clin. Invest. 102:1998;438-444.
114. Chun S., Daheshia M., Kuklin N.A., Rouse B.T. Modulation of viral immunoinflammatory responses with cytokine DNA administered by different routes. J. Virol. 72:1998;5545-5551.
115. Kay A.B. TH2-type cytokines in asthma. Ann. NY Acad. Sci. 796:1996;1-8.
116. Hogg J.C. The pathology of asthma. APMIS. 105:1997;735-745.
117. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., Krieg A.M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:1998;2555-2559.
118. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., Van Uden J., Martin-Orozco E., Gelfand E.W., Raz E. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J. Immunol. 161:1998;7054-7062.
119. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA. 1996;932879-932883.
120. Rouse B.T. Virus-induced immunopathology. Adv. Virus Res. 47:1996;353-376.
121. Gebert A. The role of M cells in the protection of mucosal membranes. Histochem. Cell Biol. 108:1997;455-470.
122. Thomas N.W., Jenkins P.G., Howard K.A., Smith M.W., Lavelle E.C., Holland J., Davis S.S. Particle uptake and translocation across epithelial membranes. J. Anat. 189:1996;487-490.
123. Siebers A., Finlay B.B. M cells and the pathogenesis of mucosal and systemic infections. Trends Microbiol. 4:1996;22-29.
124. Beagley K.W., Husband A.J. Intraepithelial lymphocytes: origins, distribution, and function. Crit. Rev. Immunol. 18:1998;237-254.
125. Abreu-Martin M.T., Targan S.R. Regulation of immune responses of the intestinal mucosa. Crit. Rev. Immunol. 16:1996;277-309.
126. Eckmann L., Jung H.C., Schurer-Maly C., Panja A., Morzycka-Wroblewska E., Kagnoff M.F. Differential cytokine expression by human intestinal epithelial cell lines regulated expression of interleukin 8. Gastroenterology. 105:1993;1689-1697.
127. Panja A., Mayer L. Antigen presentation in the intestine. Baillieres Clin. Gastroenterol. 10:1996;407-425.
128. Caplen N.J., Alton E.W.F.W., Middleton P.G., Dorin J.R., Stevenson B.J., Gao X., Durham S.R., Jeffrey P.K., Hodson M.E., Coutelle C., Huang L., Porteous D.J., Williamson R., Geddes D.M. Liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature M. 1:1995;39-46.
129. Yoshimura K., Rosenfeld M., Nakamura H., Scherer E., Pavirani A., Lecocq J.P., Crystal R. Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer. Nucleic Acids Res. 20:1992;3233-3240.
130. Stribling R., Brunette E., Liggitt D., Gaensler K., Debs R. Aerosol gene delivery in vivo, Proc. Natl. Acad. Sci. USA. 89:1992;11277-11281.
131. Tsan M.F., White J.E., Shepard B. Lung-specific direct in vivo gene transfer with recombinant plasmid DNA. Am. J. Physiol. 268:1995;L1052-L1056.
132. Davis H.L., Mancini M., Michel M.L., Whalen R.G. DNA-mediated immunization to hepatitis B surface antigen longevity of primary response and effect of boost. Vaccine. 14:1996;910-915.
133. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell. Immunol. 167:1996;72-78.
134. Chace J.H., Hooker N.A., Mildenstein K.L., Krieg A.M., Cowdery J.S. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol. 84:1997;185-193.
135. Cowdery J.S., Chace J.H., Yi A.K., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:1996;4570-4575.
136. Yamamoto S., Yamamoto Y., Kataoka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J. Immunol. 148:1992;4072-4076.
137. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845.
138. Davis H.L., Weeranta R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
139. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:1998;4463-4466.
140. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158:1997;4591-4601.
141. Macgregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., Chattergoon M.A., Baine Y., Higgins T.J., Ciccarelli R.B., Coney L.R., Ginsberg R.S., Weiner D.B. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178:1998;92-100.
142. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1- infected patients. Lancet. 351:1998;1320-1325.
143. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., Jones T.R., Hobart P., Margalith M., Ng J., Weiss W.R., Sedegah M., De Taisne C., Norman J.A., Hoffman S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
144. Ugen K.E., Nyland S.B., Boyer J.D., Vidal C., Lera L., Rasheid S., Chattergoon M., Bagarazzi M.L., Ciccarelli R., Higgins T., Baine Y., Ginsberg R., Macgregor R.R., Weiner D.B. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16:1998;1818-1821.